Skip to main content
Top

05-05-2024 | Hemolytic Uremic Syndrome | Original article

Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?

Authors: Kubra Celegen, Bora Gulhan, Kibriya Fidan, Selcuk Yuksel, Neslihan Yilmaz, Aysun Caltik Yılmaz, Beltinge Demircioğlu Kılıç, Ibrahim Gokce, Aslı Kavaz Tufan, Mukaddes Kalyoncu, Hulya Nalcacıoglu, Sare Gulfem Ozlu, Eda Didem Kurt Sukur, Nur Canpolat, Aysun K. Bayazit, Elif Çomak, Yılmaz Tabel, Sebahat Tulpar, Mehtap Celakil, Kenan Bek, Cengiz Zeybek, Ali Duzova, Birsin Ozcakar, Rezan Topaloglu, Oguz Soylemezoglu, Fatih Ozaltin

Published in: Clinical and Experimental Nephrology

Login to get access

Abstract

Background

Atypical hemolytic uremic syndrome (aHUS) is a rare, mostly complement-mediated thrombotic microangiopathy. The majority of patients are infants. In contrast to infantile-onset aHUS, the clinical and genetic characteristics of adolescence-onset aHUS have not been sufficiently addressed to date.

Methods

A total of 28 patients (21 girls, 7 boys) who were diagnosed as aHUS between the ages of ≥10 years and <18 years were included in this study. All available data in the Turkish Pediatric aHUS registry were collected and analyzed.

Results

The mean age at diagnosis was 12.8±2.3 years. Extra-renal involvement was noted in 13 patients (46.4%); neurological involvement was the most common (32%). A total of 21 patients (75%) required kidney replacement therapy. Five patients (17.8%) received only plasma therapy and 23 (82%) of the patients received eculizumab. Hematologic remission and renal remission were achieved in 25 (89.3%) and 17 (60.7%) of the patients, respectively. Compared with the infantile-onset aHUS patients, adolescent patients had a lower complete remission rate during the first episode (p = 0.002). Genetic analyses were performed in all and a genetic variant was detected in 39.3% of the patients. The mean follow-up duration was 4.9±2.6 years. At the last visit, adolescent patients had lower eGFR levels (p = 0.03) and higher rates of chronic kidney disease stage 5 when compared to infantile-onset aHUS patients (p = 0.04).

Conclusions

Adolescence-onset aHUS is a rare disease but tends to cause more permanent renal dysfunction than infantile-onset aHUS. These results may modify the management approaches in these patients.
Appendix
Available only for authorised users
Literature
17.
35.
go back to reference Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. In: Geary FG, Schaefer F, editors. Pediatric kidney disease. 2nd edn. Berlin: Springer; 2016. p. 597–632.CrossRef Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. In: Geary FG, Schaefer F, editors. Pediatric kidney disease. 2nd edn. Berlin: Springer; 2016. p. 597–632.CrossRef
Metadata
Title
Adolescence-onset atypical hemolytic uremic syndrome: is it different from infant-onset?
Authors
Kubra Celegen
Bora Gulhan
Kibriya Fidan
Selcuk Yuksel
Neslihan Yilmaz
Aysun Caltik Yılmaz
Beltinge Demircioğlu Kılıç
Ibrahim Gokce
Aslı Kavaz Tufan
Mukaddes Kalyoncu
Hulya Nalcacıoglu
Sare Gulfem Ozlu
Eda Didem Kurt Sukur
Nur Canpolat
Aysun K. Bayazit
Elif Çomak
Yılmaz Tabel
Sebahat Tulpar
Mehtap Celakil
Kenan Bek
Cengiz Zeybek
Ali Duzova
Birsin Ozcakar
Rezan Topaloglu
Oguz Soylemezoglu
Fatih Ozaltin
Publication date
05-05-2024
Publisher
Springer Nature Singapore
Published in
Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-024-02505-7
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.